Get to know our clinical trials
Clinical trial of CPI-0209 in patients with advanced solid tumors and lymphomas
THE OBJECTIVE OF THIS TRIAL IS TO FIND A DOSE OF CPI-0209 WHOSE SIDE EFFECTS ARE ACCEPTABLE AND WHICH MAY BE USEFUL IN THE TREATMENT OF PATIENTS WITH ADVANCED TUMORS. ANOTHER OBJECTIVE OF THE TRIAL IS TO MONITOR BLOOD LEVELS OF CPI-0209
Technical Summary
- PHASE I/II TRIAL OF CPI-0209 IN PATIENTS WITH ADVANCED SOLID TUMORS AND LYMPHOMAS
- Code EudraCT: 2020-04952-14
- Protocol number: 0209-01
- Promoter: Constellation Pharmaceuticals
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.